Više informacija ― Bosanski

Urticarial vasculitis je rijetko stanje koje obilježavaju dugotrajne ili ponavljajuće epizode koprivnjače. Iako njeni kožni simptomi mogu nalikovati hroničnoj koprivnji, oni su jedinstveni jer se koprivnjače zadržavaju najmanje 24 sata i mogu ostaviti tamne mrlje nakon izbljeđivanja. Iako je često nepoznatog uzroka, ponekad ga mogu izazvati određeni lijekovi, infekcije, autoimune bolesti, poremećaji krvi ili karcinomi. Neke studije su ga čak povezale s COVID‑19 i gripom H1N1. Također može zahvatiti druge organe, poput mišića, bubrega, pluća, stomaka i očiju. Iako određeni pregled tkiva može potvrditi dijagnozu, to nije uvijek potrebno. Liječenje obično počinje antibioticima, dapsonom, kolhicinom ili hidroksihlorokinom u blažim slučajevima. Za teže slučajeve mogu biti potrebni lijekovi koji potiskuju imuni sistem, poput metotreksata ili kortikosteroida. Nedavno su biološke terapije (rituximab, omalizumab, interleukin-1 inhibitors) obećavajuće za teške slučajeve.
Urticarial vasculitis is a rare clinicopathologic entity that is characterized by chronic or recurrent episodes of urticarial lesions. Skin findings of this disease can be difficult to distinguish visually from those of chronic idiopathic urticaria but are unique in that individual lesions persist for ≥24 hours and can leave behind dusky hyperpigmentation. This disease is most often idiopathic but has been linked to certain drugs, infections, autoimmune connective disease, myelodysplastic disorders, and malignancies. More recently, some authors have reported associations between urticarial vasculitis and COVID-19, as well as influenza A/H1N1 infection. Urticarial vasculitis can extend systemically as well, most often affecting the musculoskeletal, renal, pulmonary, gastrointestinal, and ocular systems. Features of leukocytoclastic vasculitis seen on histopathologic examination are diagnostic of this disease, but not always seen. In practice, antibiotics, dapsone, colchicine, and hydroxychloroquine are popular first-line therapies, especially for mild cutaneous disease. In more severe cases, immunosuppressives, including methotrexate, mycophenolate mofetil, azathioprine, and cyclosporine, as well as corticosteroids, may be necessary for control. More recently, select biologic therapies, including rituximab, omalizumab, and interleukin-1 inhibitors have shown promise for the treatment of recalcitrant or refractory cases.

Javio se 35‑godišnji muškarac s 15‑dnevnom istorijom jarko crvenih, bolnih osipa na butinama i nogama, uz bolove u zglobovima. Imao je infekciju urinarnog trakta nedelju dana prije pojave osipa. Koža je pokazivala nekoliko nježnih, prstenastih, djelomično blijedih crvenih plakova na obje strane bedara i nogu. Davao je oralni prednisone (prednizolon) 40 mg/dan tokom sedam dana, uz antihistaminik koji ne izaziva pospanost – fexofenadine (feksofenadin). U roku od sedam dana svi osipi su potpuno nestali. Tokom narednih šest mjeseci redovnih pregleda, osip se nije ponovio.
A 35-year-old man came in with a 15-day history of bright red, painful rashes on both thighs and legs, along with joint pain. He had a urinary tract infection for a week before the rash appeared. His skin showed several tender, ring-shaped, partially blanchable, red plaques on both sides of his thighs and legs. He was given oral prednisolone (40mg/day) for a week along with a non-drowsy antihistamine (fexofenadine). Within a week, all the rashes disappeared completely. There were no more rashes during the next 6 months of regular check-ups.